ACIC Pharmaceuticals Inc.
Michael Hughey currently serves as Vice President of Sales at ACIC Machinery since September 2024. Prior to this role, Michael has held multiple positions in the pharmaceutical and healthcare sectors, including Sales Director at ACIC Pharmaceutical Machinery since September 2015 and Regional Community Partnership Coordinator at Thehealthline.ca Information Network from August 2014 to September 2015. Experience in medical sales includes serving as Senior Medical Sales Representative for both Merck (2009-2014) and Sanofi (1998-2007), with a focus on Women's Health, Respiratory, and various chronic conditions. Additionally, Michael launched a new cardiovascular drug as a Primary Care Sales Representative at Novartis from 2007 to 2008, and previously worked at Canadian Tire Financial Services from 1995 to 1998 in marketing and account management roles. Michael holds a Bachelor's degree from the University of Waterloo.
ACIC Pharmaceuticals Inc.
The ACIC Group, founded in 1973 by Luciano Calenti, is a full-service pharmaceutical company. The company started in API and has a long successful array of projects satisfying customers and partners in the API business in the Generic and Brand Name Pharmaceutical field. Our strength is our joint ventures with our API manufacturing partners, as well as finished dosage form clients. All our plants are FDA inspected and meet cGMP. Our strength is to help in joint venture deals in financing companies, and financing projects as true partners in the global business. ACIC has been very active with Injectables in the last 12 years, obtaining multiple ANDA’s. ACIC built and upgraded facilities up to GMP standards in many countries. One of which is Canlac, located in Quebec. Canlac is the worlds largest lactulose Plant, now an Abbott Plant. ACIC tirelessly worked for a couple of decades with a new compound which is sold globally by a leading pharmaceutical company. ACIC Pharmaceutical Machinery was also founded, specializing in equipment for injection production, and becoming the leader in radioactive injectable production as well as in Artificial Intelligence inspection equipment for injectable products. We truly reflect our tag line, “from Molecule to Market"